Innovative Lung Health Solutions
Transforming NCD patient care through wearable digital health devices, predictive AI analysis & NMMI diagnostics.
About Us
Our MedTech Global JV Focus
The development of de novo medical technology solutions and products targeting select respiratory diseases, resulting in an optimized patient care experience that extends life expectancy. Our primary markets include India, Africa, the Middle East, and the US.
Optimizing the Patient Experience and Outcome
The Econophy Group has created TRISYNTEC, a comprehensive source provider of three digital health medtech assets that create collaborative and comprehensive treatment solutions. The collective real-world data (RWD) and real-world evidence (RWE) processes result in a higher efficacy patient care treatment, at a lower cost basis, and a shortened treatment timeline, resulting in an extended quality of life expectancy.
Our medtech product portfolio consists of three de novo type respiratory disease assets that target TB, COPD, and sleep apnea. Industry facts related to each one are as follows:
- Tuberculosis is the leading cause of death from an infectious disease worldwide.
- Global COPD prevalence is projected to approach 600 million cases worldwide by 2050.
- Sleep apnea is estimated to impact nearly 1 billion people worldwide.
COPD is widely underdiagnosed and undertreated, with up to 70-95% of cases missed or diagnosed only in advanced stages due to lack of routine spirometry, underuse of diagnostic guidelines, and patient normalization of symptoms. This results in significantly reduced quality of life, rapid disease progression, and higher mortality.
In November 2025, the Economist Impact journal published "Why the World Can't Afford to Overlook COPD." Excerpted, it cited, "Between 2020 and 2050, COPD is expected to cost the world economy US$4.3 trillion (at constant 2017 prices), according to one economic model of the impact of COPD in 204 countries and territories."
Our wearable, at-home digital health medical device has derivative capabilities and therapeutic applications for COPD, TB, sleep apnea, and in the future PTSD. It delivers real-time data and real-time evidence to a predictive AI epidemiology platform focused on respiratory diseases.
As a disease resource, it will focus on and feature an automated diagnosis tool for MDs to simplify disease diagnosis and increase its accuracy. It will also provide governments, insurance companies, healthcare providers, public and private research facilities, and pharma companies with data analytics to mitigate diagnostic errors, disease spread, and unnecessary treatment costs, becoming a primary solution provider to large-scale health industry problems.
What is the extent and impact of diagnostic error or misdiagnosis?
- Most Americans will experience at least one misdiagnosis in their lifetime.
- $750 billion, or 30% of annual health care spending, is wasted in unnecessary services and other inefficiencies, including diagnostic error, contributing to a loss of productivity in the US economy.
- Between 40,000 and 80,000 patients die each year in the US due to diagnostic errors.
- International markets require crisis-oriented POC (point of care) treatments due to a lack of an innovative solution provider with efficacy, capability, impact, and scalability that will address unmet needs and global costs versus benefit issues.
- Current diagnostic technologies have limited capabilities and efficacy.
- Vascular events, infections, and cancers account for 75% of the serious harm.
- When undiagnosed, chronic obstructive pulmonary disease (COPD) can reduce life expectancy by 0.3 to 6 years. People with severe COPD can lose 8 to 9 years of life expectancy on average.
Our JV Partner Relationships
They consist of PhDs, MDs, and senior executives of multi-country clinical research organizations (CROs), business development, and commercialization firms, who have been industry veterans for 20+ years. Our PhD data specialist partner is formerly a senior project manager at the National Institutes of Health.
Internationnal growth momentum targeting 24M at-need classified individuals
Our structure is a direct equity profit-sharing model that includes an income distribution benefit based on international revenue generated by our three medtech assets. Impact, humanitarian, and growth equity are the primary investment themes.
Initial and ongoing pharma licensing agreements will build cash reserves. We project revenue to begin before the end of Yr. 1 from pharma licensing agreements that coincide with our Phase III clinical trials, regulatory approvals, and product distributions, starting in India and Africa through our WHO joint venture engagement.
In tandem with Reg D & Reg S direct equity participations, a 3Q 2026 RWA tokenization IPO listing event is being planned that will feature our direct equity, profit-sharing model.
Contact Us
M. Damian Billy, Managing Partner
To find out more about our strategic partners, future development and growth expansion, and safe, multi-disease adaptation products, we would be happy to arrange a video conference.
TRISYNTEC, Inc., an Econophy Group company
999 Vanderbilt Beach Rd, Naples, FL 34108, USA
US direct: 239.410.4747 WhatsApp: 1+ 239.410.4747 mdbilly@econophy.com Linkedin <<https://www.linkedin.com/in/m-d-billy-874529b0/<<
Hours
Open today | 09:00 am – 05:00 pm |
Subscribe
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.